Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill ...

Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today ...

Three years after litigation started over technology used in Comirnaty, the mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an all-stock transaction valued at ...

South Korea’s LigaChem Biosciences has signed two antibody licensing agreements with US biotech NovaRock Biotherapeutics, reports Korea Biomedical Review.

USA-based biotech Vaxart has reported positive top-line results from a Phase I trial comparing its second-generation oral ...

A California-based biotech company stole the show on Wednesday after the company reported positive clinical data ...

Vaxart (NASDAQ:VXRT) stock jumped 37.9% premarket after the company reported positive early-stage data for its ...

Vaxart's (VXRT) shares soar 37% after positive early trial results for its oral norovirus vaccine. Read more here.

Globally, norovirus is associated with approximately one-fifth of all diarrhea cases (Lopman BA et al 2016, with a similar ...

Stitch Fix reported quarterly losses of six cents per share, which beat the analyst consensus estimate of losses of 11 cents per share. Quarterly revenue came in at $325.02 million, beating the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today announces a video update for stockholders by Dr. Sean Tucker. The video is ...